iShares US Medical Devices

ResMed and Oura Partner to Enhance Sleep Health Education and Care Pathways for US Members

Resona Asset Management Reduces Stake in Intuitive Surgical by 13.1%

Boston Scientific Announces Positive Results from SEISMIQ™ 4CE FRACTURE IDE Trial

FAMAR Group Signs Contract Manufacturing Agreement with GE HealthCare to Expand Iodine Contrast Agent Capacity

Stryker Agrees to Acquire Amplitude Vascular Systems for $835 Million

Boston Scientific Average Stock Price Target Cut to $83.8, Market Maintains Buy Consensus

Edwards Lifesciences EVP Donald E. Bobo Jr. Sells $1.47M in Shares

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Boston Scientific Signs $2 Billion Accelerated Share Repurchase Agreement

Boston Scientific Invests $1.5 Billion for 34% Stake in MiRus with Option to Acquire Balloon-Expandable TAVR System for $3 Billion

GEHC Receives 'Hold' Consensus from 17 Brokers, Executives Buy Shares to Show Confidence

Wall Street Zen Upgrades Intuitive Surgical to Buy; Earnings and Revenue Beat Expectations

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

Stryker partners with Max Smart Hospital to advance surgical training for robotic-assisted joint replacements

NVision Completes $55 Million B Round Led by Abbott to Expand Quantum Computing Platform

Edward Lifesciences CEO Bernard J. Zallouk Sells Shares

Abbott Laboratories Sees Rising Dividend Yield Amid High Legal Costs and Infant Formula Litigation

GE HealthCare to Showcase AI-driven Radiotherapy Tools at ESTRO 2026

GE HealthCare Director Receives Restricted Stock Units and Buys Stocks

BD Medical applies for issuance of 600 million euros of notes

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ATEC

IBBQ

Kirby McInerney LLP is investigating potential claims against Alphatec Holdings, Inc. regarding possible violations of federal securities laws. Following a disappointing first quarter report on May 5, 2026, where Alphatec's revenue fell short of expectations, the company's stock price dropped by approximately 32%. The investigation aims to determine if legal claims can be filed. Investors with information or interest are encouraged to contact the law firm.

MorningStar

Alphatec

SPDR S&P Health Equip

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

ATEC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alphatec Holdings, Inc.

RPID

Rapid Micro Biosystems has raised approximately $8.9 million through an underwritten offering and an additional $140,000 from a concurrent purchase by certain directors and officers. The offering includes 3,581,000 shares and warrants, priced at $1.955 per share unit. Proceeds will be used for working capital and corporate purposes, with both transactions expected to close around May 20, 2026.

TradingView

Rapid Micro Biosystems

Toronto Dominion Bank

Rapid Micro Biosystems Raises $8.9M Net in Underwritten Offering, Adds $140K D&O Purchase

PODD

Insulet Corp. (PODD) shares rose 1.39% to $154.61 on Tuesday, despite a broader market decline, with the S&P 500 and Dow Jones falling 0.67% and 0.65%, respectively. The stock remains 56.43% below its 52-week high of $354.88. Compared to competitors, Insulet underperformed as Eli Lilly, DexCom, and Johnson & Johnson saw gains of 3.37%, 2.86%, and 0.47%.

MarketWatch Automated

Insulet

S&P 500

Dow Jones Industrial Average

Eli Lilly

DexCom

Johnson & Johnson

Insulet Corp. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

ORMP

Oramed Pharmaceuticals Inc. reported Q1 2026 results with $0 revenue and a net income of $38.31M, improving from a net loss of $(7.64) M in Q1 2025. Diluted EPS was $0.91, up from $(0.19) a year earlier. The company shifted to managing a medical technology portfolio, reduced R&D spending, and closed strategic transactions, including the Lifeward deal.

Oramed Pharma

Lifeward

Alpha Tau Medical

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

ORAMED PHARMACEUTICALS INC. 1Q 2026: Revenue $0 Net income $38.31M, EPS $0.91— 10-Q Summary

CELC

LABU

SBIO

LABD

Delphi Diagnostics has appointed Eric Lindquist as Chief Financial Officer, effective April 1, 2026. Lindquist, an experienced oncology and life sciences executive, will lead the financial strategy as the company advances its Endocrine Activity Index® test for breast cancer treatment. His previous roles include CEO of InnoSIGN and Chief Business Officer at Celcuity. Lindquist's expertise is expected to drive growth and enhance personalized treatment options in breast cancer diagnostics.

prnewswire

Celcuity

VG Health

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bear 3X

Proshares Ultra Nasdaq Biotech

Natera

Roche

ROCHE HOLDINGS AG

17:05 ETDelphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer

Mettler-Toledo International Inc. (MTD) shares fell 2.24% to $1,050.77 on Tuesday, underperforming compared to competitors like Emerson Electric Co. and Roper Technologies. The stock is currently 31.10% below its 52-week high of $1,525.17. Overall, the stock market saw declines, with the S&P 500 down 0.67%. Trading volume was significantly higher than the 50-day average.

Mettler Toledo

Emerson Electric

Roper Tech

Agilent Tech

Factset Research

Mettler-Toledo International Inc. Stock Underperforms Tuesday When Compared To Competitors

ResMed Inc. (RMD) shares rose 1.78% to $207.78 on Tuesday, outperforming a declining market where the S&P 500 fell 0.67% and the Dow Jones dropped 0.65%. This marks the second consecutive day of gains for ResMed, although it remains 29.28% below its 52-week high of $293.81 reached on August 22nd. Trading volume was 1.4 million, surpassing the 50-day average of 1.2 million.

Resmed

iShares US Healthcare Providers

SPDR S&P Health

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh

ResMed Inc. Stock Rises Tuesday, Outperforms Market

Becton Dickinson & Co. (BDX) shares rose 3.23% to $146.95 on a challenging trading day for the market, outperforming competitors like Danaher Corp. and Medtronic PLC. The stock ended 21.56% below its 52-week high of $187.35, reached on February 24th. Trading volume was 3.9 million, surpassing the 50-day average of 2.9 million.

Becton Dickinson and

Danaher

Medtronic

Becton Dickinson & Co. Stock Outperforms Competitors On Strong Trading Day

Medtronic PLC (MDT) shares rose 1.63% to $78.58 on a challenging trading day, outperforming the S&P 500 and Dow Jones, which fell 0.67% and 0.65%, respectively. This marks the second consecutive day of gains for Medtronic, though it remains 26.10% below its 52-week high of $106.33. Competitors like Johnson & Johnson, Danaher Corp., and Abbott Laboratories also saw gains. Trading volume for Medtronic was 11.9 million, surpassing its 50-day average of 8.9 million.

Abbott Laboratories

Medtronic PLC Stock Outperforms Competitors On Strong Trading Day

Danaher Corp. (DHR) shares rose 1.94% to $167.04 on a challenging trading day for the market, outperforming competitors like Thermo Fisher, Abbott, and Medtronic. The stock is still 31.20% below its 52-week high of $242.80. Trading volume reached 5.7 million, surpassing the 50-day average of 4.6 million.

iShares US Medical Devices(IHI.US)